L

*click HERE for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 Link to Formulary

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Lacosamide, 50mg, 100mg, 150mg, 200mg tablets, 10mg/mL syrup and 10mg/mL solution for intravenous infusion (Vimpat®) SMC No 1324/18	As monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy.	Not available as not recommended in NHS Scotland	168	May 2018
Lacosamide, 50mg, 100mg, 150mg, 200mg tablets, 10mg/mL syrup and 10mg/mL solution for intravenous infusion (Vimpat®) SMC No 1301/18	As adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy. SMC restriction: patients with refractory epilepsy. Treatment should be initiated by physicians who have appropriate experience in the treatment of epilepsy.	Available in line with national guidance	167	April 2018
Lacosamide (Vimpat®) (1231/17)	As monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy.	Not available as not recommended for use in NHS Scotland	160	Apr 2017
Lacosamide (Vimpat®) (532/09)	Adjunctive therapy of partial-onset seizures in patients with epilepsy (aged 16 years and older)	GPs may prescribe under the direction of Neurology/ Epilepsy Clinic	101 99 86	Dec 10/Jan 2011 Aug/Sept 2010 Jan 2009

Lamivudine/zodovudine (Combivir®) (569/09)	HIV in paediatric patients	HOSPITAL ONLY Non-formulary	92	Aug/Sept 2009
Lanadelumab 300mg solution for injection (Takhzyro®) SMC2206	For the routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. SMC restriction: patients with HAE type I or II, who would otherwise be considered for long-term prophylaxis treatment with C1-esterase inhibitor. SMC restriction: patients with HAE type I or II, who would otherwise be considered for long-term prophylaxis treatment with C1-esterase inhibitor.	Available in line with national guidance https://www.scottishmedicines.org.uk/medicines-advice/lanadelumab-takhzyro-full-smc2206/	178	Feb 2020
Lanreotide (Somatuline® LA)	Thyrotrophic adenomas	Not recommended	64	2006
Lansoprazole oro-dispersible (Zoton FasTab®)	Hp eradication		60 55	2006
Lanthanum carbonate (Fosrenol®) (821/12)	Hyperphosphataenia in chronic renal failure	GPs may prescribe under the direction of the Renal Clinic	123 100 68	Jan 2013 Oct/Nov 2010 May 2007
Lapatinib (Tyverb®) (925/13)	Adult patients with breast cancer	Not recommended	132	Nov/Dec 2013
Lapatinib (Tyverb®) (768/12)	Advanced or metastatic breast cancer	Not recommended	115 97 86	Mar/Apr 2012 June/Jul 2010 Jan 2009
Laronidase (Aldurazyme®)	Mucopolysaccharidosis I.	HOSPITAL ONLY	47 41	2004
Latanoprost 50 micrograms/mL plus timolol 5mg/mL preservative free eye drops (Fixapost®) SMC2159	Reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues. SMC restriction: to use in patients who have proven sensitivity to preservatives.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	175	Aug 2019
Latanoprost (Monopost®)	Glaucoma and ocular hypertension	GPs under the direction of	129	Aug/Sept

(879/13)		ophthalmology Restricted to patients who require benzalkonium chloride free preparation		2013
Latanoprost (Xalacom®) (432/07)	Reduction of intraocular pressure	Formulary (Ophthalmology specialist list)	76	Jan 2008
Latanoprost (Xalatan®)	Glaucoma	Formulary (Ophthalmology specialist list)	41	2004
Lebrikizumab solution for injection in pre-filled syringe or pen (Ebglyss®) SMC2707	For the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy. SMC restriction: patients who have had an inadequate response to an existing systemic immunosuppressant such as ciclosporin, or in whom such treatment is considered unsuitable and where a biologic would otherwise be offered.	Not routinely available as local implementation plans are being developed and the ADTC is wating for further advice from local clinical experts - decision expected December 2025.		
lecanemab concentrate for solution for infusion (Leqembi®) SMC2700	for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε 4 (ApoEε4) heterozygotes or non-carriers.	Not available as not recommended for use in NHS Scotland		
lecanemab concentrate for solution for infusion (Leqembi®) SMC2700	for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε 4 (ApoEε4) heterozygotes or non-carriers. In a randomised, double-blind, phase III study, lecanemab reduced the cognitive and functional decline associated with early Alzheimer's disease compared with placebo at 18 months.	Not available as not recommended for use in NHS Scotland		
Ledipasvir/sofosbuvir 90mg/400mg film-coated tablet (Harvoni®) SMC No	Treatment of chronic hepatitis C (CHC) in adolescents aged 12 to <18 years. SMC restriction: genotype 1 and 4 CHC only	Available in line with national guidance	169	July 2018

1343/18				
Ledipasvir/sofosbuvir (Harvoni®) (1030/15)	Treatment of chronic hepatitis C (CHC) in adults. SMC restriction: genotype 1 and 4 CHC only.	HOSPTIAL ONLY - (Hep C clinic) Pending confirmation	146	
Ledipasvir/sofosbuvir (Harvoni®) (1084/15)	For the treatment of genotype 3 chronic hepatitis C (CHC) in adults. SMC Restriction: patients who are ineligible for or unable to tolerate interferon	Formulary Hospital Use Only (Hepatitis C clinic)	151	Sep/Oct 2015
Lenacapavir film-coated tablets and solution for injection (Sunlenca®) SMC2691	In combination with other antiretroviral(s) for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen, for oral loading prior to administration of long-acting lenacapavir injection. Solution for injection: in combination with other antiretroviral(s) for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.	Not recommended for use in NHS Scotland	198 not yet published	
Lenalidomide 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg hard capsules (Revlimid®) SMC2289	As monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation (ASCT).	Available in line with national guidance	181	November 2020
Lenalidomide 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg hard capsules (Revlimid®) SMC2281	In combination with rituximab (anti-CD20 antibody) for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 to 3a).	Available in line with national guidance	181	November 2020
Lenalidomide 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg hard capsules (Revlimid®) SMC2217	As combination therapy with bortezomib and dexamethasone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.	Not available as not recommended for use in NHS Scotland	176	Oct 2019
Lenalidomide 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and	As monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have	Not available as not recommended for use in NHS	172	Dec 2018

25mg hard capsules (Revlimid®) SMC2125	undergone autologous stem cell transplantation.	Scotland		
Lenalidomide 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg hard capsules (Revlimid®) SMC 1211/16	Treatment of adult patients with relapsed or refractory mantle cell lymphoma	Not available as not recommended for use in NHS Scotland	158	Dec 2016
Lenalidomide 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg capsules (Revlimid®)SMC No. 1096/15	Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. SMC Restriction: for use in patients unsuitable for thalidomide-containing regimens	Available in line with national guidance	153 157	Jan/Feb 2016 Nov 2016
Lenalidomide (Revlimid®) (942/14)	Transfusion-dependent anaemia	HOSPITAL ONLY (Haematology)	136	Mar/Apr 2014
Lenalidomide (Revlimid®) (441/08)	Multiple myeloma	Formulary NOSCAN Protocol is in development	137 96 81 79	Apr/May 2014 Apr/May 2010 July 2008 May 2008
Lenvatinib 4mg and 10mg hard capsules (Kisplyx®) SMC2476	Treatment of adults with advanced renal cell carcinoma (RCC), in combination with pembrolizumab, as first-line treatment. SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule. Lenvatinib offers an additional treatment choice in the therapeutic class of tyrosine kinase inhibitors given in combination with a PD-1/PD-L1 inhibitor for this indication.	Available in line with national guidance	190	August 2022
Lenvatinib 4mg and 10mg hard capsules (Kisplyx®) SMC2199	In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.	Available in line with national guidance	178	Feb 2020
Lenvatinib 4mg hard capsules	As monotherapy for the treatment of adult patients with	Available in line with local	174	May 2019

(Lenvima®) SMC2138	advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy	guidance for prescribing.		
Lenvatinib 4mg and 10mg hard capsules (Lenmiva®) SMC 1179/16	Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts - decision expected by January 2017.	158	Dec 2016
Lercanidipine 20mg tablet (Zanidip®)	Hypertension	Non-formulary	62	2006
Letermovir 240mg film-coated tablets (Prevymis®) SMC1338/18	For prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT). Letermovir, compared with placebo, reduced the incidence of CMV reactivation and disease in CMV-seropositive adults undergoing allogeneic HSCT.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	174	May 2019
Lercanidipine 20mg tablet (Zanidip®)	Hypertension	Non-formulary	62	2006
Letrozole (Femara®) (251/06)	Invasive early breast cancer	GPs may prescribe under the direction of the Oncology Clinic	108 Protocol 49	Aug 2011 2005
Letrozole (Femara®)	Initial adjuvant therapy in early breast cancer		58	2006
Leuprorelin acetate 3.75mg (Prostap® SR DCS) and 11.25mg (Prostap® 3 DCS) powder and solvent for prolonged-release suspension for injection in pre-filled syringe SMC2320	As treatment in pre- and perimenopausal women with advanced breast cancer suitable for hormonal manipulation. Leuprorelin offers an additional treatment choice in the therapeutic class of gonadotropin-releasing hormone (GnRH) analogues for this indication.	Not routinely available as local clinical experts do not wish to add the medicine to the forulary at this time or there is a local preference for alternative medicines	183	March 2021

Leuprorelin acetate 3.75mg (Prostap® SR DCS) and 11.25mg (Prostap® 3 DCS) powder and solvent for prolonged-release suspension for injection in pre-filled syringe SMC2319	As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in pre- and perimenopausal women at higher risk of disease recurrence (young age, high grade tumour, lymph node involvement). In women who have received chemotherapy, premenopausal status must be confirmed after completion of chemotherapy. Leuprorelin offers an additional treatment choice in the therapeutic class of gonadotropin-releasing hormone (GnRH) analogues for this indication.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	183	March 2021
Levetiracetam (Keppra®) (661/10)	Adjunctive therapy in partial onset seizures in children	GPs may prescribe under the direction of Paediatric Neurology	102 77 72	Jan/Feb 2011 Mar 2008 Sept 2007
Levetiracetam (Keppra®) (395/07)	Adjunctive therapy in juvenile myoclonic epilepsy (JME)	GPs may prescribe under the direction of Paediatrics or Adult Neurology	77 72	Mar 2008 Sept 2007
Levetiracetam (Keppra®) (396/07)	Adjunctive therapy in primary generalised tonic-clonic seizures (PGTC)	GPs may prescribe under the direction of Paediatrics or Adult Neurology	77 72	Mar 2008 Sept 2007
Levetiracetam (Keppra®) (397/07)	Monotherapy in partial onset seizures	GPs may prescribe under the direction of Paediatrics or Adult Neurology	77 72	Mar 2007 Sept 2007
Levetiracetam infusion (Keppra®)	Adjunctive therapy in partial onset seizures in patients over 4 years of age	HOSPITAL ONLY	62	2006
Levetiracetam oral solution (Keppra®)	Adjunctive therapy in partial onset seizures in adults		48	2005
Levetiracetam 750mg film-coated tablets (Keppra®)	Adjunctive therapy in partial onset seizures in adults		48	2005
Levodopa 20mg/mL +	Treatment of advanced Parkinson's disease with severe motor	Not available as not		

carbidopa monohydrate 5mg/mL + entacapone 20mg/mL intestinal gel (Lecigon®) SMC2507	fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results.	recommended for use in NHS Scotland		
Levodopa/carbidopa/entacapone (Stalevo®)	Parkinson's disease		36 35	2004
Levofloxacin 5mg/ml plus dexamethasone 1mg/ml eye drops solution (Ducressa®) SMC2511	For the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	191	Nov 2022
Levofloxacin 240mg nebuliser solution (Quinsair®)	The management of chronic pulmonary infections due to psudomonas aeruginosa in adult patients with cystic fibrosis	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	156	Sep 2016
Levomepromazine (Nozinan®)	Palliative care		93	Oct/Nov 2009
Levonorgestrel 19.5mg intrauterine delivery system (Kyleena®) SMC No 1299/18	Contraception for up to 5 years	Available in line with national guidance	167	April 2018
Levonorgestrel (Upostelle®) (938/14)	Emergency contraception	Formulary - 1st line choice	135	Feb/Mar 2014
Levonorgestrel (Jaydess®) (1036/15)	Contraception for up to 3 years.	Formulary - 2nd line choice	147	Apr 2015

Levonorgestrel (Levosert®) 20 micrograms/24 hours intrauterine delivery system (1058/15)	Contraception. Heavy menstrual bleeding.	Non Formulary Lack of clinician demand	149	Jun/Jul 2015
Lidocaine 70mg/tetracaine 70mg medicated plaster (Rapydan®) (483/08)	Surface anaesthesia	Not recommended	80	June 2008
Lidocaine 5% medicated plaster (Versatis®)	Restricted off label use in palliative care or restricted off label use in localised neuropathic pain	GPs may prescribe under the direction of Palliative Care or the Pain Clinic (Chronic Pain Team)	109 Protocol 99	Sept 2011 Aug/Sept 2010
Lidocaine 5% medicated plaster (Versatis®) (334/06)	Post-herpetic neuralgia	Formulary	109 82 67	Sept 2011 Aug/Sept 2008 Mar 2007
Linaclotide (Constella®) (869/13)	Moderate to severe irritable bowel syndrome with constipation (IBS-C)	Formulary	129 128	Aug/Sept 2013 June/July 2013
Linagliptin plus metformin (Jentadueto®) (1057/15)	For the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control when insulin and metformin alone do not provide adequate glycaemic control.	Non Formulary Lack of clinician demand	149	Jun/Jul 2015
Linagliptin 5mg film-coated tablets (Trajenta®) (850/13)	Type 2 diabetes mellitus to improve glycaemic control in adults	Monotherapy Non-formulary - alternatives preferred	125	Mar/Apr 2013

		Triple therapy with SU + metformin Non-formulary - alternatives preferred Combination with insulin Not recommended In combination with insulin with or without metformin Non Formulary - Lack of clinician support	148	May 2015
Linagliptin plus metformin (Jentadueto®) (841/13)	Type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control	Non-formulary - alternatives preferred	125	Mar/Apr 2013
Linagliptin (Trajenta®) (746/11)	Type 2 diabetes mellitus	Monotherapy: not recommended Dual therapy in combination with metformin: Non-formulary - alternatives preferred Triple therapy: Not recommended	116 114	Apr/May 2012 Feb 2012
linzagolix film-coated tablets (Yselty®) SMC2631	the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. SMC restriction: for use in patients when conventional first-line treatments (such as tranexamic acid, hormonal contraceptives and intrauterine devices) have failed or are considered unsuitable.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Lipegfilgrastim (Lonquex®) (908/13)	Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adults	Pending OHMMG decision	137	Apr/May 2014
Liposomal formulation of daunorubicin/cytarabine 44mg/100mg powder for concentrate for solution for	The treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (AML) or AML with myelodysplasia-related changes.In a randomised phase III study, in adults (aged 60 to 75 years) with high risk AML, liposomal	Available in line with national guidance	174	May 2019

infusion (Vyxeos®) SMC2130	daunorubicin/cytarabine improved overall survival when compared with a standard of care regimen.			
Liposomal irinotecan hydrochloride trihydrate (as irinotecan sucrosofate salt), 5mg/mL concentrate for solution for infusion (Onivyde®) SMC No. 1217/17	Treatment of metastatic adenocarcinoma of the pancreas, in combination with fluorouracil (5-FU) and leucovorin (folinic acid), in adult patients who have progressed following gemcitabine based therapy.	Not available as not recommended for use in NHS Scotland	160	Apr 2017
Liraglutide 6mg/ml solution for injection in pre-filled pen (Saxenda®) SM2455	Is accepted for restricted use within NHSScotland. Indication under review: as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of: • ≥30kg/m² (obese), or • ≥27kg/m² to <30kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea	Not routinely available as local implementation plans are being developed - decision expected by September 2022	189	May 2022
liraglutide 6mg/mL solution for injection in pre-filled pen (Saxenda®) SMC2378	as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of: • ≥30kg/m² (obese), or • ≥27kg/m² to <30kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. In a phase III study, liraglutide, as an adjunct to diet and exercise, was associated with significantly reduced body weight compared with placebo in patients with BMI ≥30kg/m2 or ≥27kg/m2 if they had dyslipidaemia or hypertension. The submitting company's justification of the treatment's cost in		187	Dec 2021

	relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.			
Liraglutide, 6mg/mL solution for injection in pre-filled pen (Saxenda®) SMC No: (1247/17)	As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index of • ≥ 30kg/m² (obese), or • ≥ 27kg/m² to < 30kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.	Not available as not recommended for use in NHS Scotland	162	Aug 2017
Liraglutide 6mg/ml solution for injection in pre-filled pen (Victoza®) SMC 1192/16	As monotherapy for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance or contra-indications.	Not available as not recommended for use in NHS Scotland.	157	Nov 2016
Liraglutide (Victoza®) (1044/15)	Type 2 diabetes mellitus to achieve glycaemic control in combination with: oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.	Formulary - GPs under direction of the Diabetes Clinic (Endocrine Specialist List)	148	May 2015
Liraglutide (Victoza®)	Type 2 diabetes mellitus	Formulary - GPs under direction of the Diabetes Clinic	98 Protocol with insulin (off-label) 94	Dec 10/Jan 2011 Aug/Sept 2010 Dec 09/Jan 10
lisdexamfetamine dimesylate	Part of a comprehensive treatment programme for attention	Non Formulary - absence of	151	Sep/Oct 2015

(Elvanse Adult®) (1079/15)	deficit/hyperactivity disorder (ADHD) in adults.	clinician demand		
Lisdexamfetamine dimesylate (Elvanse®) (863/13)	ADHD	GPs under the direction of child psychiatry	127	May 2013
Lixisenatide (Lyxumia®) (903/13)	Type 2 diabetes mellitus	Formulary - GPs under direction of diabetes clinic	130	Sept/Oct 2013
Lomitapide (Lojuxta®) (956/14)	Adults with homozygous familial hypercholesterolaemia (HoFH)	Not recommended	135	Feb/Mar 2014
Loncastuximab tesirine solution for infusion (Zynlonta®) SMC2609	As monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.	Available in line with national guidance	197	Apr 2024
lopinavir 80mg, ritonavir 20mg oral solution (Kaletra®) SMC No 1302/18	In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to ≤2 years.	Available in line with national guidance	167	April 2018
Lopinavir 200mg/ritonavir 50mg tablet (Kaletra®)	HIV-1	HOSPITAL ONLY (HIV Clinic)	63	2006
lorlatinib 25mg and 100mg film-coated tablets (Lorviqua®) SMC2415	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	188	April 2022
Lorlatinib 25mg and 100mg film-coated tablets (Lorviqua®) SMC 2239	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after: • alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or • crizotinib and at least one other ALK TKI In the relevant subgroup of a non-comparative phase I/II study	Available in line with national guidance	180	Sept 2020

	of previously-treated patients with ALK-positive advanced NSCLC, lorlatinib was associated with an objective response rate of approximately 40%			
Losartan 100mg/hydrochlorothiazide 12.5mg (Cozaar-Comp 100/12.5®)	Hypertension	Non-formulary	77	Mar 2008
Losartan 100mg/hydrochlorothiazide 25mg (Cozaar-Comp ®)	Hypertension	Non-formulary	60	2006
Losartan (Cozaar®)	Diabetic nephropathy	Non-formulary	47 46	2004
Losartan (Cozaar®)	Hypertension with LVH		44 43	2004
Loteprednol etabonate 0.5% 5mg/ml (Lotemax® 0.5% eye drops) (484/08)	Post operative inflammation following ocular surgery	Not recommended	80	Jun 2008
Lubiprostone (Amitiza®) (977/14)	Chronic idiopathic constipation and associated symptoms in adults.	Not recommended	140	Jul/Aug 2014
Lumacaftor-ivacaftor (Orkambi), Vertex Pharmaceuticals Europe Ltd. SMC2712	treatment of cystic fibrosis (CF) in patients aged 1 year and older (granules in sachet) or 6 years and older (film-coated tablets) who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.	Available in line with national guidance		
Lumacaftor and ivacaftor 200mg/125mg, 100mg/125mg film-coated tablets and 100mg/125mg,150mg/188mg	The treatment of cystic fibrosis in patients aged 6 years and older (tablets) and aged 2 to 5 years (granules) who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.	Not available as not recommended for use in NHS Scotland	176	Oct 2019

granules in sachets (Orkambi®) SMC2182				
Lumacaftor 200mg, ivacaftor 125mg film coated tablets (Orkambi®) SMC 1136/16	Treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CF transmembrane conductance regulator (CFTR) gene	Not available as not recommended for use in NHS Scotland	155	June 2016
lumasiran (Oxlumo) SMC2639	Treatment of primary hyperoxaluria type 1 (PH1) in all age groups.	Not available as not recommended for use in NHS Scotland	196	Feb 2024
Lumiracoxib (Prexige®) - Withdrawn November 2007	Osteoarthritis	Withdrawn	56	2006
Lurasidone (Latuda®) (994/14)	Schizophrenia in adults aged 18 years and over	Formulary - GPs may prescribe under the direction of Mental Health	142	Oct/Nov 2014
Lusutrombopag 3mg film-coated tablets (Mulpleo®) SMC 2227	For the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	178	Feb 2020
lutetium (177Lu) vipivotide tetraxetan solution for injection or infusion (Pluvicto®) SMC2517	Treatment of adult patients with prostate specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.	Not available as not recommended for use in NHS Scotland	195	December 2023
Lutetium (177Lu) oxodotreotide 370MBq/mL solution for infusion (Lutathera®) SMC No 1337/18	For the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults. In an open-label, phase III study, lutetium (177Lu) oxodotreotide significantly improved progression-free survival compared with a high dose somatostatin analogue in patients with progressive midgut neuroendocrine tumours.	Available in line with National Guidance	170	Sep 2018

Updated: 11th March 2025 Back to top Back to homepage